🔴 Pacific Biosciences is trading 5.7% down today after narrowing 2026 revenue guidance

Pacific Biosciences is trading at $2.41, down 5.68%, after narrowing its 2026 revenue guidance.

• Q3 revenue was $40.6 million; 2026 guidance is now $155 million–$160 million, down from $155 million–$165 million.
• The CFO stepped down, and the CEO is serving as interim CFO.
• The decline is unfolding amid a broader selloff: Reuters reported tech stocks were sliding as election results fueled fears of tighter AI regulation. XBI was down 5.19%; no volume data was provided.